Results 161 to 170 of about 77,990 (218)

Development of a Novel Polyleucine‐Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus

open access: yesSmall, EarlyView.
Self‐assembling amphiphilic peptide L15K6 is used as a novel immunoadjuvant for the development of a Group A Streptococcus vaccine. Robust antigen‐specific IgG responses are generated and manage to kill isolated strains of Group A Streptococcus. Cellular and bulk RNA sequencing data reveals that L15K6 regulates immune responses potentially through TLR ...
Lantian Lu   +25 more
wiley   +1 more source

Immunogenicity of Gene and Cell Therapies. [PDF]

open access: yesBioDrugs
Hofman K, Jangied P, Balu-Iyer SV.
europepmc   +1 more source

Safe and Efficient CRISPR Genome Editing of Primary Human T Cells Using a Droplet‐Based Cell Mechanoporation Platform

open access: yesSmall, EarlyView.
This study introduces a microfluidic droplet mechanoporation system for the engineering of primary human T cells. The platform enables efficient, scalable, and robust delivery of mRNA for CAR T cell production and CRISPR‐Cas9 ribonucleoproteins for genome editing, while maintaining high cell viability.
You‐Jeong Kim   +2 more
wiley   +1 more source

Cutting‐edge advances in bicyclic peptide‐based radiotracers for cancer imaging and theranostics

open access: yesVIEW, EarlyView.
Abstract Along with successful clinical approval of radiopharmaceuticals targeting somatostatin receptor subtype 2 and prostate‐specific membrane antigen, peptide‐based radiotracers have garnered the increasing attention in cancer imaging and theranostics. As a newly emerging targeting ligand in recent years, bicyclic peptides have demonstrated immense
Hengyi Ou, Xiaobo Wang, Fei Kang
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

A Case for Anti‐IgE Vaccination

open access: yesAllergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy